panobinostat + ruxolitinib

Combination of the histone deacetylase inhibitor panobinostat and the JAK1/JAK2 inhibitor ruxolitinib, explored to treat myelofibrosis by simultaneously targeting epigenetic dysregulation and overactive JAK-STAT signaling. In a phase I study in primary and post-PV/ET myelofibrosis, the combo was feasible, safe, and tolerable without dose-limiting thrombocytopenia; most patients had stable disease and 40% achieved clinical improvement by modified IWG-MRT after 6 cycles. Trial rationale arose from preclinical synergy; dosing used oral ruxolitinib twice daily with intermittent oral panobinostat on days in weeks 1 and 3 of 4-week cycles. Developers involved include Novartis, the originator of both agents for hematologic indications. This regimen is investigational; each component is individually approved (ruxolitinib for MF and PV; panobinostat for multiple myeloma). [1][7][3][6]

Brand names

Farydak + Jakafi

Other names

panobinostat and ruxolitinib